Pipelines

합성 신약 진행 프로젝트 테이블
Indication		Research	Preclinical	Phase I	Phase II	Phase III
CKD-943 Opioid Receptor Kappa agonist No CNS related adverse events (affects PNS only) License-in from Cara Therapeutics in the US	Uremic pruritus
CKD-950 A3 Adenosine receptor agonist (A3AR agonist) License-in from Can-fite Biopharma in Israel	Hepatocellular carcinoma
CKD-951 A3 Adenosine receptor agonist (A3AR agonist) License-in from Can-fite Biopharma in Israel	Metabolic dysfunction-associated steatohepatits
ACL-508(CKD-508) CETP inhibitor	Dyslipidemia
CKD-510 HDAC6 inhibitor Licensed-out to Norvatis	CV Disease
CKD-512 A2aR antagonist	Cancer
ACL-513 (CKD-513) HDAC6 inhibitor	Neurological disease
ACL-514 (CKD-514) GLP-1R agonist	Obesity / Type 2 Diabetes

바이오 의약품 진행 프로젝트 테이블
Indication		Research	Preclinical	Phase I	Phase II	Phase III
CKD-703 cMET-ADC	Cancer
CKD-704 Skyrizi (Risankizumab) Biosimilar	Plaque psoriasis, Psoriatic arthritis
CKD-706 Dupixent (Dupilumab) Biosimilar	Atopic Dermatitis, Asthma
CKD-971 IFN-alpha kinoid License-in from Neovacs in France	Lupus
Tedopi a novel T-cell epitope-based cancer vaccine icense-in from OSE Immunotherapeutics in France	HLA-A2+ non-small cell lung cancer
Pembrolizumab biosimilar Programmed death receptor-1 (PD-1)-blocking antibody License-in from Favorex in Singapore	14 cancers including melanoma
BS Candidate 1 New Biosimilar Project	Central Nervous System Diseases
BS Candidate 2 New Biosimilar Project	Rare Diseases
BS Candidate 3 New Biosimilar Project	Ophthalmic Diseases